Drug intelligence / Profile preview

vometinib

Development stage: Phase 2
Modality: Small Molecules
Administration: Oral

Overview

Vometinib is an EGFR-targeted drug. It is used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly in cases of leptomeningeal metastases. It can be administered at a double dose (160mg) in combination with intrathecal chemotherapy.

Brand names: Ivesa
Other names: volunetinibfurmonertinibalflutinibivaltinib

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on vometinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vometinib.

Explore the full profile